-
Dr. Xiubao Ren: Exploring Tumor Immunotherapy from a “Reverse” Perspective – The Practice of Reverse Immune Editing Therapy
The 5th Tianjin International Lymphoma Conference was successfully held from September 6 to 8, 2024. The conference featured 12 specialized sessions, including immunotherapy, basic translational research, and new drug development, providing a platform for international academic exchange and collaboration. During the event, Hematology Frontier invited Dr. Xiubao Ren from Tianjin Medical University Cancer Institute and…
-
Hepatology丨MELD-Na Score Predicts Long-Term Clinical Outcomes After TIPS Surgery
Traditionally, TIPS has been regarded as a bridge to liver transplantation (LT). However, recent findings suggest that some patients achieve long-term transplant-free survival (TFS) with TIPS alone. Therefore, clinicians should…
-
Dr. Shuquan Cheng: Common Factors Hindering Functional Cure in Chronic Hepatitis B
The reduction of hepatitis B surface antigen (HBsAg) levels in treated chronic hepatitis B (CHB) patients is closely linked to decreased risks of cirrhosis and even liver cancer. However, spontaneous HBsAg clearance occurs in less than 1% of patients per year. As CHB prevention and treatment guidelines continue to evolve both domestically and internationally, more…
-
Chinese Innovative Drug Takes the International Stage, Offering New Treatment Options for Intermediate and High-Risk Myelofibrosis Patients
From September 13 to 17, 2024, the European Society for Medical Oncology (ESMO) Annual Meeting is being held in Barcelona, Spain. As one of the top international oncology conferences, the event gathers experts and scholars from around the world to share cutting-edge research and discuss future developments. In the Mini Oral Session on Hematologic Malignancies,…
-
BV Combined with R2 Regimen Significantly Improves Overall Survival in Patients with Relapsed/Refractory DLBCL
The treatment of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) has always been a significant challenge and a hot topic in the field of hematologic malignancies. For these patients, treatment options are extremely limited after multiple lines of therapy. Their salvage therapy has a low remission rate and short survival time. Currently, there is an…
-
Peking Cancer Hospital Team’s PD-1/CTLA-4 Dual-Target Antibody Combined with Chemotherapy as First-Line Treatment for Advanced Gastric Cancer
Dr. Jiafu Ji, Dr. Ziyu Li, and Dr. Lin Shen from Peking Cancer Hospital have co-authored a research paper titled “Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial”, published online in Nature Medicine. The study addresses several critical clinical issues, such as the limited benefit of PD-1 monoclonal…
-
Dr. Lin Shen: Focusing on Innovative Targets, Advancing Translational Research, and Promoting the Healthy Development of Digestive System Tumors
In June 2024, the 14th Annual Meeting of the Chinese Gastrointestinal Oncology Group (CGOG) and the Peking University Digestive Tumor Forum was held in Beijing. With the theme of “Innovation, Win-Win, Excellence,” the conference focused on precision diagnosis and treatment, as well as translational research in digestive system tumors. It also covered the latest research…
-
SOHO 2024 | Dr. Eunice Wang Discusses the Latest Advances in Menin Inhibitor Research
The 12th Annual Meeting of the Society for Hematologic Oncology (SOHO 2024) took place in Houston, USA, from September 4th to 7th, 2024, gathering top experts in the field of hematologic malignancies from around the world to exchange the latest research findings and discuss new therapeutic strategies. At the conference, Dr. Eunice Wang from the…
Connecting Medical Expertise through Media